A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy
NCT05877040
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
DRUG:
Rituximab
Sponsor
Istituto Clinico Humanitas